- Home
- VSTM vs MIST Comparison
VSTM vs MIST Comparison
Compare VSTM & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- MIST
- Stock Information
- Founded
- VSTM 2010
- MIST 2003
- Country
- VSTM United States
- MIST Canada
- Employees
- VSTM N/A
- MIST N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- MIST Health Care
- Exchange
- VSTM Nasdaq
- MIST Nasdaq
- Market Cap
- VSTM 132.0M
- MIST 81.5M
- IPO Year
- VSTM 2012
- MIST N/A
- Fundamental
- Price
- VSTM $3.88
- MIST $1.43
- Analyst Decision
- VSTM Strong Buy
- MIST Strong Buy
- Analyst Count
- VSTM 8
- MIST 3
- Target Price
- VSTM $14.57
- MIST $13.00
- AVG Volume (30 Days)
- VSTM 1.1M
- MIST 177.8K
- Earning Date
- VSTM 11-06-2024
- MIST 11-11-2024
- Dividend Yield
- VSTM N/A
- MIST N/A
- EPS Growth
- VSTM N/A
- MIST N/A
- EPS
- VSTM N/A
- MIST N/A
- Revenue
- VSTM $10,000,000.00
- MIST N/A
- Revenue This Year
- VSTM N/A
- MIST N/A
- Revenue Next Year
- VSTM $125.69
- MIST N/A
- P/E Ratio
- VSTM N/A
- MIST N/A
- Revenue Growth
- VSTM N/A
- MIST N/A
- 52 Week Low
- VSTM $2.10
- MIST $1.12
- 52 Week High
- VSTM $14.22
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- VSTM 63.77
- MIST 42.50
- Support Level
- VSTM $3.11
- MIST $1.41
- Resistance Level
- VSTM $3.76
- MIST $1.53
- Average True Range (ATR)
- VSTM 0.33
- MIST 0.07
- MACD
- VSTM 0.04
- MIST -0.01
- Stochastic Oscillator
- VSTM 94.26
- MIST 26.96
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).